The small molecule drugs that reduce the levels of β-catenin, RAS, and EGFR are highly effective for the treatment of CRC because of the elevated protein levels caused by the loss of APC, which is observed in ~90% of human CRCs. Here, EGFR is linked to colorectal carcinoma.